

SUPPLEMENTAL APPLEDIX FOR THE STUDY:

**Plasma interleukin-6 level predicts the risk of arteriovenous fistula dysfunction in patients
undergoing maintenance hemodialysis**

Supplementary Table 1. Baseline demographic and laboratory data of the study population according to the tertiles of plasma IL-6 level

	Tertiles of plasma IL-6 level			<i>p</i> value
	Tertile 1 (n=98)	Tertile 2 (n=91)	Tertile 3 (n=93)	
Age (year)	59.3 ± 12.9	59.8 ± 12.5	65.2 ± 12.0	0.002 ^{e, f}
Male (n, %)	64 (65.3)	67 (73.6)	59 (63.4)	0.292
Body mass index (kg/m ²)	24.2 ± 6.2	23.6 ± 5.1	23.0 ± 5.3	0.327
Dialysis vintage (year) ^a	2.4 (1.1, 6.0)	3.5 (1.7, 6.6)	3.8 (1.6, 9.6)	0.054
Charlson Comorbidity Index	3.9 ± 1.5	4.0 ± 1.6	4.3 ± 1.5	0.150
Diabetes mellitus (n, %)	57 (58.2)	51 (56.0)	53 (57.0)	0.957
Previous history of CVD (n, %) ^b	89 (90.8)	79 (86.8)	86 (92.5)	0.419
Pre-dialysis systolic BP (mmHg)	145 ± 18	143 ± 20	145 ± 22	0.895
Location of AVF (n, %) ^c				
Forearm	20 (20.6)	21 (23.1)	28 (30.1)	0.291
Upper arm	77 (79.4)	70 (76.9)	65 (69.9)	
AVF vintage (year) ^a	2.2 (1.0, 5.0)	2.9 (1.2, 5.3)	2.9 (0.9, 5.8)	0.222
Ultrafiltration (L/session)	2.17 ± 1.06	2.42 ± 0.99	2.32 ± 1.07	0.250
Single pool Kt/V	1.61 ± 0.29	1.55 ± 0.27	1.60 ± 0.30	0.276
Blood flow rate (mL/min)	272 ± 23	265 ± 23	269 ± 22	0.059
Hemodialysis duration (hour)	3.90 ± 0.22	3.93 ± 0.18	3.93 ± 0.22	0.499
Hemodiafiltration (n, %)	18 (18.4)	22 (24.2)	30 (32.3)	0.084
Statin use (n, %)	43 (43.9)	46 (50.5)	42 (45.2)	0.626
Anti-platelet agent use (n, %)	66 (67.3)	67 (73.6)	68 (73.1)	0.566
Erythropoiesis-stimulating agent use (%)	93 (94.9)	80 (87.9)	85 (91.4)	0.228
Hemoglobin (g/dL)	10.6 ± 1.1	10.5 ± 1.2	10.2 ± 1.4	0.062
Intact parathyroid hormone (pg/dL)	241 ± 221	310 ± 256	286 ± 181	0.097
Calcium (mg/dL)	8.6 ± 0.8	8.5 ± 0.7	8.5 ± 0.9	0.506
Phosphorus (mg/dL)	4.8 ± 1.5	5.1 ± 1.3	4.6 ± 1.4	0.098
Albumin (mg/dL)	3.9 ± 0.3	3.9 ± 0.3	3.7 ± 0.3	<0.001 ^{e, f}
Alkaline phosphatase (mg/dL)	96 ± 60	108 ± 75	129 ± 88	0.010 ^e

LDL-cholesterol (mg/dL)	78 ± 25	77 ± 26	76 ± 26	0.897
Erythrocyte sedimentation rate (mm/hr)	23.7 ± 19.4	25.9 ± 15.0	40.5 ± 28.0	0.001 ^{e, f}
hs-CRP (mg/dL) ^a	0.22 (0.06, 1.49)	0.69 (0.19, 2.82)	2.40 (0.60, 8.06)	<0.001 ^{e, f}
MCP-1(pg/mL) ^a	162 (134, 205)	175 (141, 224)	162 (123, 226)	0.515
TNF- α (pg/mL) ^a	8.12 (5.33, 11.79)	10.92 (6.94, 13.61)	10.93 (7.01, 14.00)	0.002 ^{d, e}

Abbreviation: AVF, arteriovenous fistula; BP, blood pressure; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IL-6: interleukin-6 ; MCP-1,monocyte chemoattractant protein-1 TNF- α : tumor necrosis factor- α .


^a Data are expressed as median (first, third interquartile ranges) and are compared by the Kruskal-Wallis test because of their non-normal distributions.

^b Includes congestive heart failure, myocardial infarction, coronary artery disease requiring percutaneous transluminal coronary angioplasty or coronary artery bypass surgery, ventricular arrhythmia, cardiac arrest, and sudden death.

^c No information in a patient without AVF dysfunction.

^d $p < 0.05$, tertile 1 vs. tertile 2; ^e $p < 0.05$, tertile 1 vs. tertile 3; ^f $p < 0.05$, tertile 2 vs. tertile 3.

Supplementary Figure 1. Correlation between plasma IL-6 levels and high sensitivity C-reactive protein



Abbreviation: IL-6, interleukin-6; hs-CRP, high sensitivity C-reactive protein.